Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Cytosorbents Corp CTSO

Healthcare Medical Devices
CytoSorbents Corporation is engaged in the treatment of life-threatening conditions in intensive care (ICU) and cardiac surgery using blood purification via its proprietary polymer adsorption technology. The Company’s flagship product, CytoSorb, is an extracorporeal cytokine absorber, designed to reduce the cytokine storm or cytokine release syndrome that could otherwise cause massive... see more

Recent & Breaking News (NDAQ:CTSO)

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Cytosorbents Corporation - CTSO

PR Newswire December 29, 2023

Cytosorbents Corporation (CTSO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Accesswire December 28, 2023

CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation

GlobeNewswire December 28, 2023

CytoSorbents Announces Closing of $10.3 Million Registered Direct Offering

GlobeNewswire December 13, 2023

CytoSorbents Reports Third Quarter 2023 Financial and Operational Results

GlobeNewswire November 9, 2023

CytoSorbents to Report Third Quarter 2023 Operating and Financial Results

GlobeNewswire October 27, 2023

CytoSorbents to Present at the 8th Annual Dawson James Conference

GlobeNewswire October 5, 2023

CytoSorbents Highlights Upcoming Presentations at EACTS 2023: Focus on Antithrombotic Removal including the 2nd Analysis of the International STAR Registry

GlobeNewswire September 27, 2023

CytoSorbents Announces Kathleen P. Bloch To Resume as Full-Time Chief Financial Officer

GlobeNewswire September 19, 2023

CytoSorb with Ex Vivo Organ Perfusion: Transforming the Future of Solid Organ Transplantation

GlobeNewswire September 11, 2023

CytoSorbents Announces Resignation of Chief Financial Officer Alexander D'Amico

GlobeNewswire September 1, 2023

CytoSorbents Granted Expanded ANVISA Registration to Treat Shock with CytoSorb in Brazil

GlobeNewswire August 31, 2023

CytoSorbents Completes U.S. and Canadian STAR-T Pivotal Trial

PR Newswire August 14, 2023

CytoSorbents Reports Second Quarter 2023 Financial and Operational Results

GlobeNewswire August 1, 2023

CytoSorbents to Report Second Quarter 2023 Operating and Financial Results

GlobeNewswire July 26, 2023

CytoSorbents Appoints Alexander D'Amico as Chief Financial Officer

GlobeNewswire July 19, 2023

CytoSorbents And Humedics Announce Theranostic Collaboration in the Field of Liver Disease

GlobeNewswire July 11, 2023

CytoSorbents Completes Enrollment of the STAR-T Pivotal Trial

GlobeNewswire July 7, 2023

CytoSorbents Announces Independent Data Safety and Monitoring Board Recommends Completion of the Pivotal STAR-T Trial Without Modifications Following Second Scheduled Safety Review

GlobeNewswire June 15, 2023

CytoSorbents This Week to Host its Virtual Annual Stockholders Meeting and to Present at the Jefferies Healthcare Conference

GlobeNewswire June 5, 2023